stockrow
Monday 9 November 2026
Export MGNX’s income statement to Excel — free account
MacroGenics, Inc.
MGNXMacroGenics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.5 million, roughly unchanged from fiscal 2024.
- Revenue
- +47.6%
- EPS
- +154.4%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
2.33
0.11
+4.95%
Follow MGNX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 92 | 158 | 60 | 64 | 105 | 77 | 152 | 59 | 150 | 150 | 168 | +5.6% | 108 | 91 | 90 | (15.5%) | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 96.58 | 95.14 | 86.00 | 91.80 | 75.91 | 85.23 | (24.1) pt | ||||||
| EBT | (59) | (20) | (171) | (152) | (130) | (202) | (120) | (9) | (66) | (75) | (98) | +2.8% | ||||||
| EBT margin, % | (63.70) | (12.44) | (285.18) | (236.51) | (123.70) | (260.97) | (78.82) | (15.42) | (44.03) | (50.36) | (58.48) | +13.3 pt | ||||||
| Net income | (59) | (20) | (171) | (152) | (130) | (202) | (120) | (9) | (67) | (75) | (15) | +2.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 2.65 | 4.37 | 1.47 | 1.33 | 2.00 | 1.29 | 2.47 | 0.95 | 2.39 | 2.37 | 2.64 | (1.2%) | |||||
| Earnings | (1.69) | (0.54) | (4.19) | (3.16) | (2.47) | (3.37) | (1.95) | (0.15) | (1.07) | (1.18) | (0.22) | (3.9%) | ||||||
| Cash flow | (1.26) | 0.40 | (3.74) | (2.79) | (2.13) | (2.40) | (1.42) | (1.26) | (1.09) | (1.28) | (1.00) | +0.2% | ||||||
| Capex | (0.33) | (0.81) | (0.61) | (0.09) | (0.11) | (0.10) | (0.06) | (0.03) | (0.06) | (0.03) | (0.03) | (23.3%) | ||||||
| Free cash flow | (1.59) | (0.42) | (4.35) | (2.88) | (2.25) | (2.50) | (1.47) | (1.29) | (1.15) | (1.31) | (1.03) | (2.1%) | ||||||
| Book value | 7.75 | 8.29 | 5.93 | 4.80 | 5.64 | 4.00 | 2.31 | 2.46 | 1.85 | 0.88 | 0.67 | (21.5%) | ||||||
| Shares, m | 35 | 36 | 41 | 48 | 52 | 60 | 61 | 62 | 63 | 63 | 63 | +6.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 7.48 | 4.44 | 8.65 | 8.15 | 11.43 | 12.42 | 2.57 | 10.73 | 1.36 | 0.68 | 0.88 | 6.8 | ||||||
| P/B | 2.56 | 2.34 | 2.14 | 2.27 | 4.05 | 4.02 | 2.75 | 4.13 | 1.75 | 1.83 | 3.46 | 2.8 | ||||||
| EV/Sales | 4.54 | 2.55 | 4.88 | 4.89 | 8.89 | 9.36 | 1.60 | 6.93 | 0.05 | (0.55) | (0.11) | 4.3 | ||||||
| EV/FCF | (7.57) | (26.82) | (1.65) | (2.26) | (7.92) | (4.83) | (2.68) | (5.09) | (0.11) | 0.99 | 0.29 | (5.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (44) | 14 | (153) | (134) | (112) | (144) | (87) | (78) | (68) | (81) | (64) | +7.1% | |||||
| Capex | (11) | (29) | (25) | (4) | (6) | (6) | (4) | (2) | (4) | (2) | (2) | (18.0%) | ||||||
| Free cash flow | (55) | (15) | (178) | (139) | (118) | (150) | (91) | (80) | (72) | (83) | (66) | +4.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 257 | 273 | 209 | 195 | 262 | 205 | 174 | 195 | 162 | 177 | 213 | (4.1%) | |||||
| Net debt | (277) | (305) | (233) | (216) | (273) | (244) | (154) | (230) | (202) | (190) | (173) | (4.1%) | ||||||
| Shareholders’ equity | 269 | 299 | 243 | 231 | 296 | 240 | 142 | 153 | 116 | 56 | 43 | (16.1%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (17.46) | (5.73) | (48.57) | (47.10) | (37.54) | (56.62) | (38.90) | (3.13) | (23.91) | (28.78) | (4.94) | (11.3) pt | |||||
| ROIC | 0.00 | 0.00 | (1,068.54) | (744.62) | (350.76) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (20.11) | (6.91) | (63.25) | (64.12) | (49.28) | (75.49) | (62.76) | (6.15) | (49.85) | (86.95) | (32.61) | (66.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 318 | 330 | 364 | 384 | 370 | 427 | 357 | 339 | 341 | 293 | — | (0.9%) | |||||
| Revenue/emp, $m | 0.29 | 0.48 | 0.17 | 0.17 | 0.28 | 0.18 | 0.43 | 0.17 | 0.44 | 0.51 | — | +6.5% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
MacroGenics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| MSLE Satellos Bioscience Inc. | $152.6M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| ANTX AN2 Therapeutics, Inc. | $150.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $148.4M | — (loss-making) | — (loss-making) | +47.62% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | |
| SION Sionna Therapeutics, Inc. | $148.3M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| NGEN NervGen Pharma Corp. | $143.1M | — (loss-making) | — | — | n/m | −48.10% (below 0%: shrinking) | — | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $140.4M | — | — | — | — | — | — | — | Compare |
| ADAG Adagene Inc. Sponsored ADR | $134.3M | — | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | Compare |
| INO Inovio Pharmaceuticals, Inc. | $125.6M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $145.7M | — | — | — | — | −11.08% | 99.63% | 0.00% |
Pay and ownership Proxy statement filed 8 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2024 | 6.40m | 1.78m | 14.22 |
| 2023 | 3.71m | 6.49m | 42.08 |
Ownership
Directors and executive officers, together
13.60%
Armistice Capital, LLC
9.90%
Scott Koenig, M.D., Ph.D.
5.90%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement